Sight Sciences, Inc. SGHT shares traded lower Monday after the company issued third-quarter total revenue guidance below estimates and cut full-year 2023 revenue guidance below estimates.
What To Know: Sight Sciences lowered full-year revenue guidance from between $89 million and $94 million to between $80 million and $82 million, versus the $92.12 million estimate.
Third-quarter total revenue is anticipated to be between $19 million and $20 million, versus the $23.72 million estimate.
The company announced the appointment of Matthew Link as its CEO as well, with Link stating, "I am delighted to be joining Sight Sciences at this critical juncture as the glaucoma and dry eye categories are undergoing significant transformation. Sight Sciences is a leader in eyecare technology innovation with a portfolio and pipeline of products that are elevating the standard of care."
"I am ready to leverage my strong commercial strategy and development background in high-growth medtech to help Sight Sciences achieve its fullest potential. I look forward to working with Paul and the Sight Sciences team to improve the lives of our patients and help the Company achieve its growth and profitability objectives."
Related Link: Intel Stock Defiant Despite Recent Tech Worries
SGHT Price Action: Shares of SGHT were flat in the after-hours session at the time of publication, according to Benzinga Pro.
Image by Paul Diaconu from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
